OncoSec CEO Sends Letter to Fellow Shareholders

Dec 12, 2019 8:30am EST

OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value

Dec 09, 2019 8:30am EST

OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO™ and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

Dec 05, 2019 8:30am EST

OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing

Dec 04, 2019 9:00am EST

OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements

Dec 02, 2019 8:00am EST

OncoSec to Present at the 31st Annual Piper Jaffray Healthcare Conference

Nov 26, 2019 8:30am EST

OncoSec Presents Immunological Data Associated with Positive Tumor Response from TAVO™ KEYNOTE Studies Evaluating Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Nov 12, 2019 8:30am EST

OncoSec to Present TAVO™ Immune Biomarker Data Associated with Positive Clinical Response from Ongoing KEYNOTE Studies at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Nov 05, 2019 8:30am EST

OncoSec Provides Letter to Shareholders Regarding Recently-Announced $30 Million USD Strategic Investment at a Premium to Market

Oct 21, 2019 9:00am EDT

OncoSec Announces New Peer-Reviewed Data for TAVO™ in Virus-Associated Skin Cancer Published in Clinical Cancer Research

Oct 15, 2019 8:30am EDT